- Home
- KROS vs LXRX Comparison
KROS vs LXRX Comparison
Compare KROS & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- LXRX
- Stock Information
- Founded
- KROS 2015
- LXRX 1995
- Country
- KROS United States
- LXRX United States
- Employees
- KROS N/A
- LXRX N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- LXRX Health Care
- Exchange
- KROS Nasdaq
- LXRX Nasdaq
- Market Cap
- KROS 565.0M
- LXRX 552.4M
- IPO Year
- KROS 2020
- LXRX 2000
- Fundamental
- Price
- KROS $15.17
- LXRX $1.34
- Analyst Decision
- KROS Buy
- LXRX Buy
- Analyst Count
- KROS 14
- LXRX 5
- Target Price
- KROS $20.56
- LXRX $3.23
- AVG Volume (30 Days)
- KROS 1.1M
- LXRX 2.3M
- Earning Date
- KROS 11-06-2025
- LXRX 11-06-2025
- Dividend Yield
- KROS N/A
- LXRX N/A
- EPS Growth
- KROS N/A
- LXRX N/A
- EPS
- KROS 0.47
- LXRX N/A
- Revenue
- KROS $232,844,000.00
- LXRX $58,432,000.00
- Revenue This Year
- KROS $6,657.47
- LXRX $66.55
- Revenue Next Year
- KROS N/A
- LXRX N/A
- P/E Ratio
- KROS $32.70
- LXRX N/A
- Revenue Growth
- KROS 85820.30
- LXRX 1504.83
- 52 Week Low
- KROS $9.12
- LXRX $0.28
- 52 Week High
- KROS $72.37
- LXRX $1.66
- Technical
- Relative Strength Index (RSI)
- KROS 49.12
- LXRX 46.54
- Support Level
- KROS $14.86
- LXRX $1.30
- Resistance Level
- KROS $15.30
- LXRX $1.40
- Average True Range (ATR)
- KROS 0.58
- LXRX 0.07
- MACD
- KROS 0.02
- LXRX -0.02
- Stochastic Oscillator
- KROS 72.85
- LXRX 13.33
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.